Live Breaking News & Updates on அங்கீகரிக்கப்பட்டது மருந்துகள்

Stay updated with breaking news from அங்கீகரிக்கப்பட்டது மருந்துகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Worldwide CNS Therapeutics Industry to 2025 - Awareness Campaigns Launched by Pharma Companies to Benefit the Market


Share this article
Share this article
ResearchAndMarkets.com s offering.
The global market for CNS Therapeutics is projected to reach US$137.7 billion by 2025, driven by the urgent need to address the unmet medical needs of neurological disorders. Diseases of the brain and mind range from epilepsy, stroke, migraine, Alzheimer`s, Parkinson`s, dementia, multiple sclerosis, brain injuries, neuroinfections, schizophrenia, psychosis and other mental disorders. With unmet needs continuing to persist, societal and healthcare burden continues to increase.
Stroke and infections such as meningitis and encephalitis continue to be the leading cause of disability worldwide, pushing up the cost of nursing care, hospice and bringing down quality of life. The unmet needs are evident in all phases of drug development i.e. identification of therapeutic targets; optimization of lead compounds; gaps in toxicity and pharmacokinetics studies; and slow resolution of ethical issues, amon ....

United States , United Kingdom , Effexor Venlafaxine , Epidiolex Cannabidiol , Purdue Pharma , Eli Lilly Emgality , Risperdal Consta , Eli Lilly , Invega Sustenna , Laura Wood , Age Group , Lack Of Evidence , A New Research Demonstrates Effectiveness Of Gluconate , Janssen Pharmaceuticals Inc , Astrazeneca Plc , Teva Pharmaceutical Industries Ltd , Merck Co Inc , Pfizer Inc , Pharma Companies , Abbvie Inc , Sunovion Pharmaceuticals Inc , Otsuka Pharmaceutical Co Ltd , Fabre Kramer Pharmaceuticals Inc , Alkermes Plc , Roche Ltd , Neurocrine Biosciences Inc ,

US Rheumatoid Arthritis Drug Market Patent Price Insight Report 2026

US Rheumatoid Arthritis Drug Market Patent Price Insight Report 2026
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Rheumatoid Arthritis , Napproved Drugs , முடக்கு கீல்வாதம் , அங்கீகரிக்கப்பட்டது மருந்துகள் ,

Review Of The 4th Amendment Of China's Patent Law - Intellectual Property


To print this article, all you need is to be registered or login on Mondaq.com.
Twelve years from the third amendment of China s patent law,
the fourth amendment was approved by the Standing Committee of the
National People s Congress on October 17, 2020. The new
amendment will take effect on June 1, 2021. This article provides a
detailed review of the changes from the current patent law.
Enhanced Protection of Patent Rights
The first aspect of changes relates to enhanced protection of
patent rights. Specifically, it includes punitive damages,
increased statutory damage, reversed burden of proof, increased
fine for passing‐off, and extended time limit for initiating ....

National People Congress On , Standing Committee , Property Administration , Products Administration , China National , National People , Punitive Damages , Increased Statutory , Reversed Burden , Increased Fine , Extended Time , Patent Term , Intellectual Property Administration , Patent Linkage , State Council , Patent Information Registration , Napproved Drugs , Drug Products , National Medical , Early Resolution Mechanism , Drug Patent Disputes , Trial Version , Drug Experimental Data , Waxman Act , New Grace Period , Patent Right Evaluation ,